It had to happen - combine monoclonal antibody therapy with Zytiga antihormonal therapy. Yervoy (Ipilimumab) is a monoclonal antibody aimed at the CTLA-4 antigen which reactivates the Cytotoxic T-Lymphocytes to recognise and destroy tumour cells. Zytiga is now established as a standard of care in prostate cancer therapy and so many new drugs with potential against prostate cancer are now compared with Zytiga therapy.
Yervoy in combination with Zytiga respresents an interesting combination since the Zytiga will starve the tumour of androgenic hormones whilst the Yervoy will stimulate the killer T-Cells to attack the tumour and should work against tumours that have metastasized. A clinical trial is currently underway to test the safety and efficacy of this combination with oral Zytiga being taken daily along with Prednisone, and Yervoy administered IV every 3 weeks for 4 cycles. The effect on PSA response will be examined along with progression free survival time.
No comments:
Post a Comment